Abstract
Abstract Fibroblast growth factor receptor (FGFR) plays a major role in maintaining retinal pigment epithelium cells. Drugs that inhibit the FGFR pathway block the activation of the mitogen-activated protein kinase pathway, leading to the synthesis of antiapoptotic proteins and secondary subretinal fluid accumulation. Erdafitinib, a potent tyrosine kinase inhibitor of fibroblast growth factor receptors (FGFRs) is one such antitumour drug that has shown significant efficacy in patients with urothelial carcinoma with FGFR alterations. We present a case report demonstrating the bilateral subretinal fluid accumulation due to erdafitinib.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
